A cost comparison of medical management and transurethral needle ablation for treatment of benign prostatic hyperplasia during a 5-year period

Journal of Urology

Volumn 173, Issue 6, 2005, Pages 2090-2093

  Naslund, M J ^a,d   Carlson, A M ^b   Williams, M J ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Data Intelligence Consultants LLC   (United States)

^c MEDTRONIC INC   (United States)

^d NONE   (United States)

Author keywords

Costs and cost analysis; Finasteride; Prostatic hyperplasia; Tamsulosin; Transurethral resection of prostate

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN;

ARTICLE; COMBINATION CHEMOTHERAPY; DRUG COST; HEALTH CARE COST; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SURGICAL INSTRUMENT; TRANSURETHRAL NEEDLE ABLATION;

EID: 18744377517     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000158451.30419.66     Document Type: Article

References (19)

1. Roehrborn, C. G. and McConnell, J. D.: Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Campbell's Urology, 8th ed. Edited by P. C. Walsh, A. B. Retik, E. D. Vaughan, Jr. and A. J. Wein. Philadelphia: W. B. Saunders Co., vol. 2, sect. VI, chapt. 38, pp. 1297-1330, 2002
2. AUA Practice Guidelines Committee: AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol, 170: 530, 2003
3. Blute, M. L. and Larson, T.: Minimally invasive therapies for benign prostatic hyperplasia. Urology, suppl., 58: 33, 2001
4. Hill, B., Belville, W., Bruskewitz, R., Issa, M., Perez-Marrero, R., Roehrborn, C. et al: Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol, 171: 2336, 2004
5. McConnell, J. D., Roehrborn, C. G., Bautista, O. M., Andriole, G. L., Jr., Dixon, C. M., Kusek, J. W. et al: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med, 349: 2387, 2003
6. Vaughan, E. D., Jr.: Medical management of benign prostatic hyperplasia-are two drugs better than one? N Engl J Med, 349: 2449, 2003
7. Albertsen, P. C., Pellissier, J. M., Lowe, F. C., Girman, C. J. and Roehrborn, C. G.: Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study. Clin Ther, 21: 1006, 1999
8. Manyak, M. J., Ackerman, S. J., Blute, M. L., Rein, A. L., Buesterien, K., Sullivan, E. M. et al: Cost effectiveness of treatment for benign prostatic hyperplasia: an economic model for comparison of medical, minimally invasive and surgical therapy. J Endourol, 16: 51, 2002
9. Norby, B., Nielsen, H. V. and Frimodt-Moller, P. C.: Cost-effectiveness of new treatments for benign prostatic hyperplasia: results of a randomized trial comparing the short-term cost-effectiveness of transurethral interstitial laser coagulation of the prostate, transurethral microwave thermotherapy and standard transurethral resection or incision of the prostate. Scand J Urol Nephrol, 36: 286, 2002
10. De La Rosette, J. J., Floratos, D. L., Severens, J. L., Kiemeney, L. A., Debruyne, F. M., Pilar Laguna, M.: Transurethral resection vs microwave thermotherapy of the prostate: a cost-consequences analysis. BJU Int, 92: 713, 2003
11. Foley, C. L., Taylor, C. and Kirby, R. S.: Counting the cost of treating benign prostatic hyperplasia. BJU Int, 93: 250, 2004
12. Kobelt, G., Spangberg, A. and Mattiasson, A.: The cost of feedback microwave thermotherapy compared with transurethral resection of the prostate for treating benign prostatic hyperplasia. BJU Int, 93: 543, 2004
13. First Databank November, 2004
14. CMMS. 42 CFR Parts 405 and 414. Medicare Program, Changes to Medicare payment for drugs and physician fee schedule payments for calendar year 2004. Federal Register 69: November 15, 2004
15. Data on file. Pharmetrics, Inc. Watertown, Massachusetts
16. Naslund, M., Bay-Nielsen, H., Holtgrewe, L., Homma, V. and Melchior, H.: Economics of BPH. In: Proceedings of the 5th International Consultation on Benign Prostatic Hyperplasia. Plymouth, United Kingdom: Health Publications Limited-Plymbridge Distribution, chapt. 2, pp. 69-78, 2001
17. Brealey, R. A. and Meyers, S. C.: How to calculate present values. In: Principles of Corporate Finance, 4th ed. New York: McGraw Hill, chapt. 3, pp. 29-45, 1991
18. Zlotta, A. R., Giannakopoulos, X., Maehlum, O., Ostrem, T. and Schulman, C. C.: Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcomes up to 5 years from 3 centers. Eur Urol, 44: 89, 2003
19. Chandrasekar, P. and Virdi, J. S.: Transurethral needle ablation of the prostate (TUNA®)-a prospective study, six year followup. J Urol, suppl., 165: 294, abstract 1210, 2001